Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance
Fiona J McCallum, Kristina EM Persson, Freya JI Fowkes, Linda Reiling, Cleopatra K Mugyenyi, Jack S Richards, Julie A Simpson, Thomas N Williams, Paul R Gilson, Anthony N Hodder, Paul R Sanders, Robin F Anders, David L Narum, Chetan Chitnis, Brendan S Crabb, Kevin Marsh, James G Beeson
JOURNAL OF LEUKOCYTE BIOLOGY | WILEY | Published : 2017
Antibodies play a key role in acquired human immunity to Plasmodium falciparum (Pf) malaria and target merozoites to reduce or prevent blood-stage replication and the development of disease. Merozoites present a complex array of antigens to the immune system, and currently, there is only a partial understanding of the targets of protective antibodies and how responses to different antigens are acquired and boosted. We hypothesized that there would be differences in the rate of acquisition of antibodies to different antigens and how well they are boosted by infection, which impacts the acquisition of immunity. We examined responses to a range of merozoite antigens in 2 different cohorts of ch..View full abstract
Funding was provided by the National Health and Medical Research Council of Australia (project grant, program grant, and senior research fellowship to J.G.B.; Infrastructure for Research Institutes Support Scheme Grant; postgraduate research fellowships to F.J.M.; and Early Career Fellowship to J.S.R.); the Wellcome Trust (project grant to K.M. and J.G.B.; program grant to K.M.; and fellowships to K.M. and T.N.W.); Australian Research Council (Future Fellowship to F.J.I.F.); and Victorian State Government Operational Infrastructure Support grant. This research was supported, in part, by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health. The authors thank all study participants and staff at the Kenya Medical Research Institute (KEMRI; Kilifi), Ross Coppel (Monash University for providing recombinant MSP4), and Arzum Cubuk (Burnet Institute) for help with correcting the manuscript.